Skip to main content

SPRUCE BIOSCIENCES INC

For the period ended Jun 30, 2024. Filed Aug 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 12, 2024

SPRB$46.67-5.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Stockholders’ Equity

(in thousands, except share amounts)

Additional · Accumulated Other · Total
Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’
SharesAmountCapitalLossDeficitEquity
Balance as of March 31, 202441,154,799$4$275,477$—$(208,857)$66,624
Issuance of common stock related to employee stock purchase plan118,534—52——52
Issuance of common stock related to vesting of restricted stock units, net of tax withholdings29,266—(11)——(11)
Stock-based compensation——1,685——1,685
Net loss————(9,181)(9,181)
Balance as of June 30, 202441,302,599$4$277,203$—$(218,038)$59,169
Additional · Accumulated Other · Total
Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’
SharesAmountCapitalLossDeficitEquity
Balance as of January 1, 202441,029,832$4$273,737$—$(197,232)$76,509
Exercise of common stock options120,328—180——180
Issuance of common stock related to employee stock purchase plan118,534—52——52
Issuance of common stock related to vesting of restricted stock units, net of tax withholdings33,905—(13)——(13)
Stock-based compensation——3,247——3,247
Net loss————(20,806)(20,806)
Balance as of June 30, 202441,302,599$4$277,203$—$(218,038)$59,169
Additional · Accumulated Other · Total
Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’
SharesAmountCapitalGain (Loss)DeficitEquity
Balance as of March 31, 202339,746,116$4$270,285$(188)$(162,104)$107,997
Exercise of pre-funded warrants800,000—8——8
Issuance of common stock related to employee stock purchase plan102,984—99——99
Issuance of common stock related to vesting of restricted stock units, net of tax withholdings61,592—(71)——(71)
Stock-based compensation——1,219——1,219
Unrealized gain on available for sale securities———133—133
Net loss————(12,824)(12,824)
Balance as of June 30, 202340,710,692$4$271,540$(55)$(174,928)$96,561
Additional · Accumulated Other · Total
Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’
SharesAmountCapitalGain (Loss)DeficitEquity
Balance as of January 1, 202323,601,004$3$218,354$(558)$(149,313)$68,486
Exercise of pre-funded warrants800,000—8——8
Issuance of common stock related to employee stock purchase plan102,984—99——99
Issuance of common stock related to vesting of restricted stock units, net of tax withholdings90,704—(94)——(94)
Issuance of common stock and warrants, net of offering costs of $2,72116,116,000150,894——50,895
Stock-based compensation——2,279——2,279
Unrealized gain on available for sale securities———503—503
Net loss————(25,615)(25,615)
Balance as of June 30, 202340,710,692$4$271,540$(55)$(174,928)$96,561
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.